2009/09/29     Schering Plough (Organon) extends the current research program on nuclear receptors with Shanghai Genomics. This program started in 2006 and has lasted for more than 3 years. It represents an important starting point for our research service business.

2009/09/28     Dr. Ying Luo of Shanghai Genomics, was invited to present the most recent progress of the company's drug development at China Clinical Trials Outsourcing Congress 2009 held in Manchester, United Kingdom.

2009/09/10     Dr. Ying Luo, President and CEO of GNI Ltd. and General Manager of Shanghai Genomics, Inc., was invited to present at the Japan Biotech Forum at London, United Kingdom.

2009/08         Dr. Ying Luo, President and CEO of GNI Ltd. and General Manager of Shanghai Genomics, Inc., received the "Outstanding Innovation and Entrepreneurship Award" at the event of "10th Anniversary of Focus on Zhangjiang".

2009/07/14          Shanghai Genomics' leading drug candidate for liver fibrosis, F351, has received patent granted by Australia. This is the first step for Shanghai Genomics to seek global protection for F351 in US, Europe, Canada, and Japan. The company has received patent grant in China in 2007. It is currently in Phase I clinical trial in the Peking Union Hospital. At the same time, the company also received patent grant for F647's use in anti-liver fibrosis and anti-acute lung injury. This strenghtened the company's intellectual property position of key products.

2009/03/26     Dr. Ying Luo gave a keynote speech at the 2009 & 8th Annual China Pharma, Life Science & Healthcare Industry Summit Week (CPHIS 2009) in Shanghai.

2009/02/10     Dr. Ying Luo chaired the IBC Life Sciences Conference: Access India & China. He also presented the drug co-development model of Shanghai Genomics at the conference.

2009/01/21     Shanghai Genomics' leading drug candidate F647 demonstrated good results in Phase II trial for Radiation Pneumonitis. In 2008, Shanghai Genomics has completed Phase II trial of F647 for Idiopathic Pulmonary Fibrosis. NDA filing is also be prepared for Idiopathic Pulmonary Fibrosis."

© 2007~2018 shanghaigenomics.com. All rights reserved. Shanghai ICP 08017875